We are using our industry-leading capabilities and innovative, proprietary technologies to uniquely solve intractable therapeutic challenges for patients around the world.

Patient-Focused Therapies

Patients suffering from attention-deficit/hyperactivity disorder (ADHD), pain, addiction and diseases of the central nervous system (CNS) deserve effective therapies that are unique and address unmet patient needs. Tris Pharma is committed to delivering these medications.

Tris has generated a comprehensive and expanding portfolio of leading ADHD treatments to meet the needs of both children and adults with the condition. In addition, our pipeline has the potential to improve the lives of people with pain, addiction and diseases of the central nervous system (CNS), including narcolepsy and spasticity, while significantly reducing the tremendous global burden of these diseases and conditions.

“Innovating in our field is about taking calculated risks and focusing on patients, and we’ve always done both.”

Ketan Mehta, Tris Pharma Founder and CEO